CD8A and neoplasm: Nevertheless, pre-clinical mouse studies have revealed a potential of dual anti-tumour activities of 4-1BB mAb by which both Treg depletion and CD8 T cell promotion can be achieved by smartly exploiting antibody isotypes and FcγR-availability (95).